P2Y13 Receptor
P2Y13 receptor is an ADP-responsive Gi-coupled P2Y receptor that regulates purinergic signaling through cAMP-linked and calcium-related cellular responses[1]. Mechanistically, ADP acting on P2Y13 receptors can inhibit ATP release from human red blood cells, supporting a negative-feedback role in extracellular nucleotide control[2]. In bone models, P2Y13 regulates extracellular ATP metabolism, osteoblast responses to mechanical loading, and bone turnover in receptor-deficient mice[3][4]. Compared with related isoforms, P2Y13 shares high sequence homology and Gi coupling with P2Y12, but experimental studies distinguish P2Y13 functions in osteoblasts, red blood cells, hepatocytes, and neuronal systems[1][2][3][5]. For research applications, ADP and ADP-like agonists support P2Y13 activation studies, while agonist potency analysis helps compare calcium/IP3 release, cAMP inhibition, and GTPγS binding endpoints[6].
References:
- [1]. Marteau F, et al. Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. [Content Brief]
- [2]. Wang L, et al. ADP acting on P2Y13 receptors is a negative feedback pathway for ATP release from human red blood cells. Circ Res. 2005 Feb 4;96(2):189-96. [Content Brief]
- [3]. Wang N, et al. The P2Y13 receptor regulates extracellular ATP metabolism and the osteogenic response to mechanical loading. J Bone Miner Res. 2013 Jun;28(6):1446-56. [Content Brief]
- [4]. Wang N, et al. Reduced bone turnover in mice lacking the P2Y13 receptor of ADP. Mol Endocrinol. 2012 Jan;26(1):142-52. [Content Brief]
- [5]. Collins DM, et al. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). Cell Signal. 2008 Dec;20(12):2356-69. [Content Brief]
- [6]. Dsouza C, et al. Characterization of Potency of the P2Y13 Receptor Agonists: A Meta-Analysis. Int J Mol Sci. 2021 Mar 27;22(7):3468. [Content Brief]
-
P2Y13 Receptor Related Products (4)
Related Products (4)
-
2-MeS-ADP trisodium
0 ImagesSynonyms: 2-Methylthioadenosine diphosphate trisodium; 2-Methylthio-ADP trisodium2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1.
-
2-(Phenylethynyl)-ATP ammonium
0 ImagesCat. No.: HY-107752ACAS No.: 851191-73-62-(Phenylethynyl)-ATP (ammonium) is a selective and potent GPR17 agonist with an EC50 of 35 pM. 2-(Phenylethynyl)-ATP (ammonium) also shows weak activation of P2Y Receptor. 2-(Phenylethynyl)-ATP (ammonium) can be used for the research of neurological disease.
-
2-MeSADP
0 ImagesCat. No.: HY-108648ACAS No.: 34983-48-7Synonyms: 2-Methylthioadenosine diphosphate; 2-Methylthio-ADP2-MeSADP is a P2Y receptor agonist, with an EC50 of 5 nM for human P2Y12, EC50 values of 19 nM and 13 nM for human P2Y13, and an EC50 of 6.2 nM for mouse P2Y13. It shows slightly higher selectivity for P2Y12 over human P2Y13. 2-MeSADP triggers increases in intracellular calcium levels, Gi-mediated cAMP inhibition, adenylate cyclase inhibition and downstream signal transduction. 2-MeSADP can be used in research related to glaucoma.
-
MRS2603
0 ImagesCat. No.: HY-123202CAS No.: 860623-35-4MRS2603 is a pyridoxal derivative. MRS2603 antagonized both P2Y1 and P2Y13 receptors.
